Please provide your email address to receive an email when new articles are posted on . Continued lecanemab treatment linked to significant disease-modifying effects. No new safety signals were ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

VIENNA — Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE ...

New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also ...

Venetoclax-obinutuzumab therapy shows sustained PFS and OS benefits over chemoimmunotherapy in untreated CLL patients with coexisting conditions. The CLL14 trial's 6-year follow-up confirms >50% of ...

MANCHESTER, England — Febuxostat (Uloric) did not appear to increase the risk for major adverse cardiovascular (CV) events (MACEs) when compared with no urate-lowering therapy (ULT) in people with ...

Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven ...